Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow
06 April 2018
Read about REPROCELL's visit from Derek Mackay, the Scottish National Party’s Cabinet Secretary for Finance and the Constitution, on 05 April 2017
REPROCELL’s David Bunton addresses the Scottish Parliament
21 March 2018
Discussing how sectors, such as life science, are affected by Scotland’s economic performance and what actions are required to make the economy more inclusive, innovative and international. Topics include key factors in company success, SME’s and government partnership.
Patient-derived tumor organoids recapitulate clinical treatments
14 March 2018
REPROCELL is currently working to develop a highly predictive three-dimensional (3D) human micro-intestine model that can be used to test new drugs for the treatment of IBD and gastrointestinal cancers.
REPROCELL’s Prof Stefan Przyborski to chair the SMi 2nd Annual Conference on 3D Cell Culture – London UK, 21-22 February 2018
24 January 2018
Read the announcement that REPROCELL Europe’s CSO Prof Stefan Przyborski will chair the first day of the 3D Cell Culture conference.
Formation of human tissue to improve drug testing and reduce animal research
19 January 2018
REPROCELL’s Alvetex, a scaffold for 3D cell culture and bioengineered tissue models, is in the Durham University (UK) News yesterday.
REPROCELL Launches New Global Website
15 January 2018
Today, REPROCELL rolled out its new comprehensive global website demonstrating the synergies and power of the full portfolio of products and services.
REPROCELL Announces Research Collaboration with Q Therapeutics and Dr Mahendra Rao
29 November 2017
Learn more about REPROCELL's collaborative research agreement with Q therapeutics to develop new iPS Cell therapies for central nervous system diseases
REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services
08 November 2017
PALO ALTO, CA, November 8, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research services and procurement of human biospecimens, announced today that REPROCELL has selected the Science Exchange platform.
Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017
27 September 2017
REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017.
Nicola Sturgeon: interview at the official opening of REPROCELL’s Centre for Predictive Drug Discovery (YouTube video)
10 August 2017
Video: First Minister Nicola Sturgeon officially opened the new European headquarters of a life sciences company which is set to generate 15 new jobs and safeguard a further three following new investment.
Press Release: Nicola Sturgeon, First Minister of Scotland, opens REPROCELL European Headquarters in Glasgow
10 August 2017
REPROCELL Europe Ltd (REPROCELL), a leading provider of products and services for research in stem cells, drug discovery, human tissues and 3D cell culture and a member of the REPROCELL Group, has opened its European headquarters in Glasgow, UK.
REPROCELL and Fox Chase Cancer Center Partner to Open Multi-Site Biosample Repository in India
24 May 2017
REPROCELL and Fox Chase Cancer Center today announced a joint venture to open a multi-site bio-sample repository facility in India.
REPROCELL and Fox Chase Cancer Center Form Strategic Alliance to Accelerate Biomarker and Genetic Discovery
13 April 2017
REPROCELL and Fox Chase Cancer Center have announced a strategic alliance aimed at accelerating oncology discovery and translational studies, read more
REPROCELL Europe’s CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research
03 March 2017
REPROCELL Europe’s CEO, Dr David Bunton presented at the recent NC3Rs meeting on the use of human tissues in cancer research. The conference considered the potential for human tissue models to help reduce clinical drug attrition and provide more relevant models of cancer
REPROCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan
14 February 2017
Read about the REPROCELL CEO's meeting with Fiona Hyslop, Cabinet Secretary for Culture, Tourism and External Affairs for the Scottish Government
Scottish Enterprise Association Honours REPROCELL with Annual Awards Nomination
07 February 2017
Read about REPROCELL CEO Dr David Bunton's nomination for the Scottish Enterprise Association Life Science Business Leadership Award
Prof Stefan Przyborski to chair the SMi Group’s 3D Cell Culture 2017 Conference (22-23 Feb)
13 January 2017
The SMi Group’s 3D Cell Culture 2017 Conference (22-23 Feb) will be chaired by REPROCELL Europe’s chief scientific officer (CSO), Professor Stefan Przyborski. He will also be giving the first lecture in the conference.
Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products
22 November 2016
REPROCELL announces an entrustment contract with Healios K.K. for sample testing support of human clinical trials conducted by Healios.
Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development
16 November 2016
Today, REPROCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. for the development of a 3D model system derived from human iPS cells.
Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy
11 November 2016
Read about REPROCELL's partnership with Steminent Biotherapeutics to develop and commercialize Steminent’s allogeneic stem cell therapy product Stemchymal.